Amir El Farra
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Amir El Farra has a total of 13 co-authors. Here are the top co-authors by number of shared publications:
- Borivoj Sekulic
Clinical Center of Vojvodina, Clinic of Hematology, Novi Sad, Serbia
2 shared publications - Ivanka Percic
Faculty of Medicine, Clinic of Hematology, University of Novi Sad, University Clinical Center of Vojvodina, Novi Sad, Serbia
2 shared publications - Aleksandar Savic
Faculty of Medicine, University of Novi Sad
1 shared publication - Danijela Agic
Faculty of Medicine, Clinic of Hematology, University of Novi Sad, University Clinical Center of Vojvodina, Novi Sad, Serbia
1 shared publication - Dunja Bjelogrlic
Clinic of Hematology, University Clinical Center of Vojvodina, Novi Sad, Serbia
1 shared publication - Ivana Milosevic
Clinic for Hematology, University Clinical Center of Vojvodina, Novi Sad, Serbia
1 shared publication
Latest Publications
- 20 May 2024
- Published by Taylor & Francis in Leukemia & Lymphoma
- Vol. 65 (10) , 1535-1537
Successful pregnancy outcome in a patient with myelofibrosis receiving ruxolitinib treatment in the first trimester
- 20 May 2024
- Published by Taylor & Francis in Leukemia & Lymphoma
- Vol. 65 (10) , 1535-1537
Successful pregnancy outcome in a patient with myelofibrosis receiving ruxolitinib treatment in the first trimester
- 17 September 2023
- Published by Springer Nature in Indian Journal of Hematology and Blood Transfusion
- Vol. 40 (2) , 213-219
Is There a Role for Growth and Differentiation Factor-15 in B-Cell Lymphoproliferative Neoplasms?
Growth and differentiation factor-15 (GDF-15) correlates with worse outcome of many tumours and any cause mortality. Data about its role in lymphoproliferative neoplasms (LPN) are scarce. Our research aimed to reveal the correlation between GDF-15 and standard laboratory parameters of LPN activity, and to get insight into the possible value of this cytokine assessment in lymphoma patients. Prospective research included 40 patients treated for aggressive or indolent LPN, and 31 with indolent LPN on “watch and wait” regimen. Analyses were performed before and after treatment in treated patients and on two separate occasions in the “watch and wait” group. ELISA technique with R&D assays according to the manufacturer manual, from stored sera at − 70 °C was used for GDF-15 level measurement. Statistical analyses were performed by IBM SPSS Statistics 22 using descriptive and inferential statistics. As appropriate, differences between groups were assessed by two tailed t-test, Mann–Whitney or x2 test. Spearman Rank Order Correlation was done to correlate GDF-15 with standard laboratory markers of disease activity. All tests are two-tailed with significance level p < 0. 05. GDF-15 (p = 0.028) and fibrinogen (p = 0.001) concentrations increased after treatment in indolent lymphoma patients while β2 microglobulin decreased (p < 0.001). GDF-15 positively correlated with β2microglobulin before (p < 0.001) and after (p = 0.031) therapy. There were no differences in any of the aforementioned parameters in the “watch and wait” group during observation. A positive correlation between GDF-15 and β2 microglobulin in patients with indolent LPN who need treatment suggests potential value in risk assessment.
- 17 September 2023
- Published by Springer Nature in Indian Journal of Hematology and Blood Transfusion
- Vol. 40 (2) , 213-219
Is There a Role for Growth and Differentiation Factor-15 in B-Cell Lymphoproliferative Neoplasms?
Growth and differentiation factor-15 (GDF-15) correlates with worse outcome of many tumours and any cause mortality. Data about its role in lymphoproliferative neoplasms (LPN) are scarce. Our research aimed to reveal the correlation between GDF-15 and standard laboratory parameters of LPN activity, and to get insight into the possible value of this cytokine assessment in lymphoma patients. Prospective research included 40 patients treated for aggressive or indolent LPN, and 31 with indolent LPN on “watch and wait” regimen. Analyses were performed before and after treatment in treated patients and on two separate occasions in the “watch and wait” group. ELISA technique with R&D assays according to the manufacturer manual, from stored sera at − 70 °C was used for GDF-15 level measurement. Statistical analyses were performed by IBM SPSS Statistics 22 using descriptive and inferential statistics. As appropriate, differences between groups were assessed by two tailed t-test, Mann–Whitney or x2 test. Spearman Rank Order Correlation was done to correlate GDF-15 with standard laboratory markers of disease activity. All tests are two-tailed with significance level p < 0. 05. GDF-15 (p = 0.028) and fibrinogen (p = 0.001) concentrations increased after treatment in indolent lymphoma patients while β2 microglobulin decreased (p < 0.001). GDF-15 positively correlated with β2microglobulin before (p < 0.001) and after (p = 0.031) therapy. There were no differences in any of the aforementioned parameters in the “watch and wait” group during observation. A positive correlation between GDF-15 and β2 microglobulin in patients with indolent LPN who need treatment suggests potential value in risk assessment.